New Natural Compound Plumbagin Discovered as Potent Cancer Enzyme Inhibitor

γ-Glutamylcyclotransferase (GGCT) is an enzyme crucial for glutathione metabolism, a pathway vital for cellular defense against oxidative stress and drug detoxification. GGCT is often overexpressed in various cancers, including prostate cancer and colorectal cancer, where it contributes to tumor growth, progression, and resistance to chemotherapy. Despite its importance, there's a significant lack of specific and potent small-molecule inhibitors targeting GGCT to explore its therapeutic potential in oncology. This study specifically addresses the urgent need to identify novel chemical entities that can effectively inhibit GGCT activity.

Plumbagin demonstrated potent and dose-dependent inhibition of GGCT activity, with an IC50 value of approximately 0.5 µM in cell-free assays. At a concentration of 1 µM, Plumbagin achieved a remarkable 95% reduction in GGCT enzymatic activity compared to untreated controls. This makes Plumbagin one of the most potent natural product inhibitors of GGCT discovered to date, significantly surpassing the efficacy of previously reported weak inhibitors. Kinetic studies further suggested that Plumbagin acts as a non-competitive inhibitor, binding to an allosteric site on the GGCT enzyme, which could offer advantages in overcoming resistance mechanisms. The study definitively established Plumbagin as a novel, highly effective inhibitor of γ-Glutamylcyclotransferase (GGCT), exhibiting an IC50 of 0.5 µM and achieving 95% inhibition at 1 µM.